Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
75 participants
OBSERVATIONAL
2013-05-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Determine intra-LV pressure-time profile non-invasively using recently developed echo Doppler VFM analysis and applanation tonometry and myocardial elastic properties, in HF subjects (both HFNEF and HFREF) compared to normal volunteers.
2. Correlate calculated intra-LV pressure parameters with NT ProBNP levels.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Central to diagnosis of HF is estimation of intra-cardiac pressure, which can only be obtained from invasive catheterization.
This proposed study aim to:
1. Determine intra-LV pressure-time profile non-invasively using recently developed echo Doppler VFM analysis and applanation tonometry and myocardial elastic properties, in HF subjects (both HFNEF and HFREF) compared to normal volunteers.
2. Correlate calculated intra-LV pressure parameters with NT ProBNP levels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Healthy Volunteers will undergo the following studying procedures:
Echocardiography Arterial tonometry
Echocardiography
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
Arterial tonometry
A noninvasive method to obtain arterial pressure waveform.
Heart Failure Patients
Patients will undergo the following studying procedures:
NTproBNP Echocardiography Arterial tonometry
NTproBNP
To assess its level in the blood, as a marker of heart failure presence and severity.
Echocardiography
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
Arterial tonometry
A noninvasive method to obtain arterial pressure waveform.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NTproBNP
To assess its level in the blood, as a marker of heart failure presence and severity.
Echocardiography
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
Arterial tonometry
A noninvasive method to obtain arterial pressure waveform.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. has presented to hospital with a primary diagnosis of Heart Failure or
2. is attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either:
* resulted in a hospital admission (primary diagnosis) or
* was treated in out-patient clinic
* LVEF \>50% is used as cut-off value for HFNEF and LVEF \< 50% for HFREF.
* NT-proBNP within 7 days of admission \> 220pg/ml. If there is no result available, NT-proBNP on the same day as echo scan must be \> 220pg/ml.
Exclusion Criteria
* History of valvular disease, i.e. rheumatic heart disease and/or having undergone valvular replacement.
* Isolated right heart failure due to pulmonary disease.
* Presence of haemodynamically significant obstructive lesions of left ventricular outflow tract.
* History of any organ transplant or who was on a transplant list (life expectancy \< 6 months at time of enrollment).
* Presence of end-stage renal failure.
* Pregnancy.
* The patient is unable to provide written informed consent.
21 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart Centre Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thu Thao Le, PHD
Role: PRINCIPAL_INVESTIGATOR
National Heart Centre Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Heart Centre Singapore
Singapore, Singapore, Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013/365/C
Identifier Type: -
Identifier Source: org_study_id